More info
Active ingredients
Hopantenic acid
Release form
Pills
Composition
Active ingredient: calcium hopantenate (Pantogam) 500 mg, Excipients: methylcellulose, calcium stearate, magnesium hydroxycarbonate, talc.
Pharmacological effect
Nootropic agent, has neurometabolic, neuroprotective and neurotrophic properties. It increases the resistance of the brain to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, has an anticonvulsant effect, reduces motor excitability with simultaneous ordering of behavior. Enhances mental and physical performance. It contributes to the normalization of GABA in chronic alcohol intoxication and the subsequent abolition of ethanol. Shows analgesic effect.
Pharmacokinetics
After ingestion is rapidly absorbed in the digestive tract. Tmax - 1 hour. The highest concentrations are in the liver, kidneys, in the wall of the stomach and skin. Penetrates the BBB. Not metabolized. It is excreted unchanged within 48 hours: 67.5% of the dose taken - with urine, 28.5% - with feces.
Indications
Children with perinatal encephalopathy from the first days of life. Different forms of cerebral palsy. Mental retardation of varying severity, including behavioral disorders. Violations of the psychological status of children in the form of a general mental retardation, specific speech disorders, motor functions and their combination the formation of school skills (reading, writing, counting, etc.). Hyperkinetic disorders, including attention deficit hyperactivity syndrome. Neurosis-like states (with panying primarily clonic form, ticks, inorganic encopresis and enuresis) .Snizhenie mnestiko-intellectual productivity due to arteriosclerotic changes in cerebral vessels, while the primary forms of senile dementia, organic brain damage of traumatic, toxic, neyroinfektsionnogogeneza. Schizophrenia with cerebral organic deficiency (in combination with psychotropic drugs). Extrastrapyramidal disorders in organic brain diseases (myoclonus epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.),as well as for the treatment and prevention of extrapyramidal syndrome caused by the administration of neuroleptics. Epilepsy with a slowdown of mental processes and a decrease in cognitive productivity in conjunction with anticonvulsants. Psycho-emotional overload, reduced mental and physical performance, to improve concentration and memorization. Neurogenic disorders of urination (pollakiuria, imperative urges, imperative urinary incontinence).
Contraindications
Hypersensitivity. Acute severe kidney disease. Pregnancy (i trimester syrup). Pregnancy (pills). Phenylketonuria (syrup, contains aspartame). Breastfeeding period (pills). Children age up to 3 years (pills).
Use during pregnancy and lactation
Use in the first trimester of pregnancy is contraindicated.
Dosage and administration
Adults: single dose - 0.25–1 g, daily - 1.5–3 g; children: single dose - 0.25–0.5 g, daily - 0.75–3 g. The course of treatment is 1–4 months, in some cases up to 6 months. After 3-6 months, it is possible to repeat the course of treatment. With epilepsy in combination with anticonvulsants - 0.75–1 g / day. The course of treatment is up to 1 year or more. With extrapyramidal neuroleptic syndrome in combination with therapy, the daily dose is up to 3 g, treatment for several months. In extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (combined treatment) - 0.5–3 g / day. The course of treatment is up to 4 months or more. With the consequences of neuroinfections and TBI, 0.25 g 3-4 times a day. To restore performance at elevated loads and asthenic conditions - 0.25 g 3 times a day. For the treatment of extrapyramidal syndrome caused by the administration of neuroleptics, for adults - 0.5–1 g 3 times a day; children - 0.25–0.5 g 3-4 times a day. The course of treatment is 1-3 months. For ticks: for children - 0.25–0.5 g 3–6 times a day, for 1–4 months. For urination disorders: for adults - 0.5–1 g 2–3 times a day; children - 0.25–0.5 g each (daily dose - 25–50 mg / kg). The course of treatment is 1-3 months. For children with various pathologies of the nervous system, depending on age, the drug is recommended at a dose of 1-3 g. Tactics of prescribing the drug: increasing the dose for 7–12 days, taking the maximum dose for 15–40 days and gradually reducing the dose until withdrawal Pantogam for 7–8 days.The break between coursework Pantogam, as for any other nootropic drugs, is from 1 to 3 months.
Side effects
Allergic reactions are possible rhinitis, conjunctivitis, skin rashes. Others may cause sleep disturbances or drowsiness, tinnitus (these symptoms are usually short-lived and do not require discontinuation of the drug).
Interaction with other drugs
It prolongs the effect of barbiturates, enhances the effects of anticonvulsants, nootropic and CNS stimulating agents, the action of local anesthetics (procaine). It prevents the side effects of phenobarbital, carbamazepine, antipsychotics (neuroleptics). The effect of hopantenic acid is enhanced in combination with glycine, ksifiponom.
special instructions
Long-term therapy with hopantenic acid in combination with other nootropic and CNS-stimulating agents is not recommended.